Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Li

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 1, 2011
Will risk evaluation and mitigation strategies ever be accepted?Edward C Li
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2011
A quick REMS update and a clinical focusEdward C Li
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
Exploring pharmacy and drug policy concernsEdward C Li
Journal of the National Comprehensive Cancer Network : JNCCN|September 28, 2010
Preliminary report: the development of the NCCN Comparative Therapeutic Index™ as a clinical evaluative process for existing data in oncologyEdward C Li, Jessica DeMartino
Clinical Therapeutics|December 25, 2003
Zoledronic acid: a new parenteral bisphosphonateEdward C Li, Lisa E Davis
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
Insights and perspectives in the clinical and operational management of cancer-related anemiaJennifer M Hinkel, Edward C Li, Stephen L Sherman
Drug Discovery Today|January 10, 2015
Considerations in the early development of biosimilar productsEdward C Li, Richat Abbas, Ira A Jacobs, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 22, 2024
Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the USJeanine A Flanigan, Marie Yasuda, Chi-Chang Chen, et al.
Journal of Oncology Practice|September 19, 2018
Spending on Antineoplastic Agents in the United States, 2011 to 2016Samuel J Hong, Edward C Li, Linda M Matusiak, et al.
Pharmacotherapy|June 26, 2010
Drug-induced QT-interval prolongation: considerations for cliniciansEdward C Li, John S Esterly, Shaunte Pohl, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of the National Comprehensive Cancer Network : JNCCN|July 1, 2011
Will risk evaluation and mitigation strategies ever be accepted?Edward C Li
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2011
A quick REMS update and a clinical focusEdward C Li
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
Exploring pharmacy and drug policy concernsEdward C Li
Journal of the National Comprehensive Cancer Network : JNCCN|September 28, 2010
Preliminary report: the development of the NCCN Comparative Therapeutic Index™ as a clinical evaluative process for existing data in oncologyEdward C Li, Jessica DeMartino
Clinical Therapeutics|December 25, 2003
Zoledronic acid: a new parenteral bisphosphonateEdward C Li, Lisa E Davis
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
Insights and perspectives in the clinical and operational management of cancer-related anemiaJennifer M Hinkel, Edward C Li, Stephen L Sherman
Drug Discovery Today|January 10, 2015
Considerations in the early development of biosimilar productsEdward C Li, Richat Abbas, Ira A Jacobs, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 22, 2024
Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the USJeanine A Flanigan, Marie Yasuda, Chi-Chang Chen, et al.
Journal of Oncology Practice|September 19, 2018
Spending on Antineoplastic Agents in the United States, 2011 to 2016Samuel J Hong, Edward C Li, Linda M Matusiak, et al.
Pharmacotherapy|June 26, 2010
Drug-induced QT-interval prolongation: considerations for cliniciansEdward C Li, John S Esterly, Shaunte Pohl, et al.
Pageof 2